The adeno-associated viral vector (AAV) based gene therapy field bore the brunt of the biotech sector slump in 2022, but New Jersey-based Rocket Pharmaceuticals emerged relatively unscathed – a fact its CEO attributed to ignoring an ill-advised “land grab” for the biggest targets in genetic diseases.
Many other pre-market companies had to slash headcount and budgets last year due to limited R&D progress and dwindling cash...